Butterfly Network, Inc. (NYSE: BFLY)

Sector: Healthcare Industry: Medical Devices CIK: 0001804176
Market Cap 735.80 Mn
P/B 3.61
P/E -9.21
P/S 8.32
ROIC (Qtr) -36.72
Div Yield % 0.00
Rev 1y % (Qtr) 4.51
Total Debt (Qtr) 18.41 Mn
Debt/Equity (Qtr) 0.09
Add ratio to table...

About

Butterfly Network, Inc., a digital health company, is revolutionizing the healthcare industry with its innovative combination of portable ultrasound technology, intuitive software, and educational solutions. The company's main business activities involve the development and marketing of handheld, portable ultrasound devices that can be used by healthcare practitioners to perform ultrasound imaging. Butterfly Network operates in the digital health sector, specifically focusing on ultrasound technology. The company's operations span across various...

Read more

Investment thesis

Bull case

  • Strong tangible asset base of 282.14M provides 15.32x coverage of total debt 18.41M, indicating robust asset backing and low credit risk.
  • Tangible assets of 282.14M provide exceptional 11.62x coverage of deferred revenue 24.29M, showing strong service capability backing.
  • Operating cash flow of (24.85M) fully covers other non-current liabilities (6.86M) by 3.62x, showing strong long-term stability.
  • Strong cash position of 144.23M provides 3.07x coverage of other current liabilities 47.02M, indicating excellent liquidity.
  • Cash reserves of 144.23M provide robust 2.87x coverage of current liabilities 50.33M, indicating strong short-term solvency.

Bear case

  • Investment activities of (2.67M) provide weak support for R&D spending of 35.77M, which is -0.07x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of (24.85M) provides insufficient coverage of deferred revenue obligations of 24.29M, which is -1.02x, raising concerns about future service delivery capabilities.
  • The company's operating cash flow of (24.85M) shows concerning coverage of stock compensation expenses of 22.31M, with a -1.11 ratio indicating potential earnings quality issues.
  • Free cash flow of (27.52M) provides weak coverage of capital expenditures of 2.67M, with a -10.30 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (78.51M) show weak coverage of depreciation charges of 8.83M, with a -8.89 ratio indicating high capital intensity and potential reinvestment needs.

Product and Service Breakdown of Revenue (2024)

Geographical Breakdown of Revenue (2024)

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 173.80 Bn 32.73 5.47 12.94 Bn
2 SYK Stryker Corp 141.15 Bn 43.48 5.62 15.86 Bn
3 MDT Medtronic plc 123.47 Bn 25.92 3.55 29.10 Bn
4 BSX Boston Scientific Corp 112.80 Bn 38.92 5.62 11.44 Bn
5 EW Edwards Lifesciences Corp 45.66 Bn 33.38 7.76 0.70 Bn
6 DXCM Dexcom Inc 27.52 Bn 32.91 5.90 1.34 Bn
7 STE STERIS plc 24.13 Bn 34.08 4.14 2.05 Bn
8 PODD Insulet Corp 17.33 Bn 70.38 6.87 1.01 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 2.09 2.13
EV to Cash from Ops. EV/CFO -24.42 2.75
EV to Debt EV to Debt 32.95 17.25
EV to EBIT EV/EBIT -7.73 2.89
EV to EBITDA EV/EBITDA -7.76 4.53
EV to Free Cash Flow [EV/FCF] EV/FCF -22.04 29.36
EV to Market Cap EV to Market Cap 0.82 25.09
EV to Revenue EV/Rev 6.86 32.80
Price to Book Value [P/B] P/B 3.61 4.73
Price to Earnings [P/E] P/E -9.21 -2.04
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 40.22
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.59
Dividend per Basic Share Div per Share (Qtr) 0.00 0.10
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.37
Interest Coverage Int. cover (Qtr) -54.79 196.93
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 43.87 -152.08
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 53.84 8,476.58
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -0.44
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 19.62 -792.16
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 16.61 3.79
EBIT Growth (1y) % EBIT 1y % (Qtr) 19.48 -301.80
EBT Growth (1y) % EBT 1y % (Qtr) 18.79 -121.44
EPS Growth (1y) % EPS 1y % (Qtr) 28.26 -87.51
FCF Growth (1y) % FCF 1y % (Qtr) 51.24 10.43
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 69.56 38.21
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.30 0.55
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.02
Cash Ratio Cash Ratio (Qtr) 2.87 1.80
Current Ratio Curr Ratio (Qtr) 4.80 4.18
Debt to Equity Ratio Debt/Equity (Qtr) 0.09 1.20
Interest Cover Ratio Int Coverage (Qtr) -54.79 196.93
Times Interest Earned Times Interest Earned (Qtr) -54.79 196.93
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -78.80 -2,396.63
EBIT Margin % EBIT Margin % (Qtr) -88.76 -2,478.60
EBT Margin % EBT Margin % (Qtr) -90.38 -2,690.42
Gross Margin % Gross Margin % (Qtr) 43.20 30.80
Net Profit Margin % Net Margin % (Qtr) -90.30 -2,821.53